To appraise the clinical and cost-effectiveness of ADI-PEG 20 in combination with pemetrexed and cisplatin within its marketing authorisation for mesothelioma
Status In progress
Decision Selected
Process STA 2018
ID number 1575


Key events during the development of the guidance:

Date Update
08 May 2019 In progress. Referred 17 October 2018

For further information on our processes and methods, please see our CHTE processes and methods manual